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BACKGROUND AND CONTEXT
Few studies have analyzed the impact of Cocid-19 in liver
transplant recipients and the association of co-
morbidities, immunosuppression and ageing on the
mortality risk.
NEW FINDINGS
Age > 70 and tacrolimus use had respectively a negative
and a positive independent effect on survival. The role of
co-morbidities was strongly influenced by the dominant
effect of age as the number of comorbidities increased
with the increasing age of the recipients.
LIMITATIONS
Although we attempted to collect data on major co-
variables there remains the possibility of missing
confounders.
IMPACT
Thees findings should encourage clinicians to keep
Tacrolimus at the usual dose as it may be beneficial
when treating COVID-19.BACKGROUND AND AIMS: Despite concerns that liver trans-
plant (LT) recipients may be at increased risk of unfavorable
outcomes from COVID-19 due the high prevalence of co-mor-
bidities, immunosuppression and ageing, a detailed analysis of
their effects in large studies is lacking. METHODS: Data from
adult LT recipients with laboratory confirmed SARS-CoV2
infection were collected across Europe. All consecutive pa-
tients with symptoms were included in the analysis. RESULTS:
Between March 1 and June 27, 2020, data from 243 adult
symptomatic cases from 36 centers and 9 countries were
collected. Thirty-nine (16%) were managed as outpatients
while 204 (84%) required hospitalization including admission
to the ICU (39 of 204, 19.1%). Forty-nine (20.2%) patients died
after a median of 13.5 (10–23) days, respiratory failure was the
major cause. After multivariable Cox regression analysis, age
>70 (HR, 4.16; 95% CI, 1.78–9.73) had a negative effect and
tacrolimus (TAC) use (HR, 0.55; 95% CI, 0.31–0.99) had a
positive independent effect on survival. The role of co-
morbidities was strongly influenced by the dominant effect of
age where comorbidities increased with the increasing age of
the recipients. In a second model excluding age, both diabetes
(HR, 1.95; 95% CI, 1.06–3.58) and chronic kidney disease (HR,
1.97; 95% CI, 1.05–3.67) emerged as associated with death
CONCLUSIONS: Twenty-five percent of patients requiring
hospitalization for COVID-19 died, the risk being higher in pa-
tients older than 70 and with medical co-morbidities, such as
impaired renal function and diabetes. Conversely, the use of
TAC was associated with a better survival thus encouraging
clinicians to keep TAC at the usual dose.
Keywords: COVID-19; Liver transplantation; Outcome;
Tacrolimus.
he current coronavirus disease 2019 (COVID-19)Abbreviations used in this paper: ALT, alanine aminotransferase; CI,
confidence interval; CNI, calcineurin inhibitor; COVID-19, coronavirus
disease 2019; CsA, cyclosporine A; ELITA, European Liver Transplantation
Association; ELTR, European Liver Transplant Registry; ICU, intensive
care unit; LT, liver transplant; MMF, mycophenolate mofetil; mTOR,
mammalian target of rapamycin; SARS-CoV2, severe acute respiratory
syndrome coronavirus 2; TAC, tacrolimus.
Most current article
© 2021 by the AGA Institute
0016-5085/$36.00
https://doi.org/10.1053/j.gastro.2020.11.045Tpandemic has presented unforeseen challenges to
health care systems worldwide, with several issues
remaining unmet. To date, firm knowledge on disease evo-
lution, risk factors, and optimal management in specific
categories of patients is lacking. All transplant recipients are
potentially vulnerable to severe acute respiratory syndrome
coronavirus (CoV) 2 (SARS-CoV-2) infection, with immune
suppression, aging, and metabolic or cardiovascular
comorbidities likely being risk factors for symptomatic
disease and its severe complications.1 Liver transplant (LT)
patients, in particular, represent one of the largest immu-
nosuppressed cohorts in Europe, with 102,116 alive re-
cipients being reported in the European Liver Transplant
Registry (ELTR), 42,432 (41.6%) of whom are in their 60s
and 12,669 in their 70s or older.2
At present, available data related to COVID-19 in LT
patients are limited to a small number of case series,3–5 to
preliminary reports from 2 international registries,6–8 and
to a single international prospective cohort of 57 patients.9
All authors agreed that greater case numbers were urgently
required to accurately improve our understanding of indi-
vidual risk in LT recipients. Thus, a large-scale collaborativestudy promoted by the European Liver Transplant Associ-
ation (ELITA) and European Liver Transplant Registry
(ELTR) was performed, the main aim being the search for
risk factors associated with mortality during the COVID-19




ELITA called for a COVID-19 study, which was circulated on
March 30, 2020, among 149 LT centers affiliated to ELTR and
located in 30 European countries. All centers that reported at least
1 case were provided with a database and instructions on how to
record structured data. Data collection was managed by ELTR.
Responses were received from 114 centers (76.5%), with 56
centers (38%) having observed COVID-19 in adult LT recipients
between March 1 and May 19, 2020. The study included all pa-
tients with symptoms and with SARS-CoV-2 infection confirmed
by a positive result on a reverse-transcriptase polymerase chain
reaction (RT-PCR) assay of a specimen collected on a nasopha-
ryngeal swab or on bronchoalveolar lavage.
Data Collection and Definitions
Demographic and clinical data, including clinical symptoms
or signs at presentation, laboratory, and radiologic results during
Figure 1. Flowchart shows the selection of the study
population.








COVID-19 management, as well as administered antiviral ther-
apies and antithrombotic prophylaxis were retrospectively
collected. All laboratory tests and radiologic assessments were
performed at the discretion of the treating physician. Serum
creatinine was converted to mg/dL for analysis. Information on
baseline immunosuppression and on changes during COVID-19,
namely reduction or discontinuation, was also obtained.
Obesity was defined as a given body mass index of
>30 kg/m2. Liver injury during COVID-19 was defined as
alanine aminotransferase (ALT) level >30 IU/L for male pa-
tients and 19 IU/L for female patients in those with normal
ALT levels at the last outpatient visit.10 Hepatic flare was
defined as ALT level 5 times the upper limit of normal. The
time on study started at occurrence of COVID-19 symptoms.
All submitted files from each center were manually reviewed
to assess for data quality, completeness, and inconsistencies. In
addition, submitting clinicians were contacted and asked to
provide corrections or data integration whenever needed.
Ethical and Regulatory Approval
Data were collected in accordance with General Data Pro-
tection Regulation, the European Union legislation, and the
ELTR privacy policy.
Statistical Analysis
Analysis was led by the Research Centre on Public Health,
University of Milan-Bicocca, Monza, Italy. A descriptive analysis
of the cohort was performed on the overall population and after
stratifying the population by site of management: at home, in
general wards, or in intensive care units (ICUs). Categorical
variables are summarized through percentages, and continuous
variables through median, first quartile and third quartile. Cat-
egorical variables were compared using the c2 or Fisher’s exact
tests; continuous variables were compared using the Mann-
Whitney U test or the Kruskal-Wallis test, when appropriate.
All tests were 2-sided and used a significance level of 0.05.
The rates of missing data for each variable were reported.
For each patient, the time between the date of COVID-19
symptoms and death or end of follow-up was computed, and
the association between mortality and baseline patients’ char-
acteristics was evaluated through univariate Cox’s proportional
hazard models. All characteristic analyzed in the univariate
model were included in a stepwise selection process that iden-
tified the best multivariate model. The same process was
repeated after excluding age from potential predictors. Given the
exploratory nature of the study and the limited sample size, a 0.1
significance level was established to retain predictors in the final
multivariate models possibly favoring the tracing of borderline
significant associations that could be the basis for further studies
on wider samples. All statistical analyses were conducted using
SAS 9.4 software (SAS Institute, Inc, Cary, NC) and R 4.0.0 soft-
ware (R Core Team, Vienna, Austria). The map was drawn using
QGIS 3.10 software (QGIS Development Team).
Results
Demographic and General Characteristics of
Patients
The COVID-19 pandemic was not uniformly experienced
in Europe, with large areas being spared. This explains whyof the 111 centers responding to the ELITA/ELTR call, only
36 centers from 9 European countries observed at least 1
patient with RT-PCR–confirmed SARS-CoV-2 infection
(Figures 1 and 2). Of the 29,981 alive patients in regular
follow-up at the participating centers, 258 (0.9%) have been
consecutively reported in the registry. Excluded from the
study were 11 patients (4.3%) who were asymptomatic, in
whom the RT-PCR test was performed according to sur-
veillance protocols in case of contact with a SARS-CoV-2–
positive individual. Four additional patients were excluded
because they were aged <18 years. The remaining 243
symptomatic patients were considered for statistical anal-
ysis, with 39 patients (16%) receiving home care, and the
remaining 204 requiring hospitalization (Figure 2). Of these,
167 patients (68.7%) were treated in a general ward and 37
in ICUs. Baseline patient characteristics are reported in
Table 1. Thirty-two LT recipients with COVID-10 analyzed in
this study were also included in the report from Becchetti
et al.9
Comorbidities
A total of 111 patients (45.7%) had arterial hyperten-
sion, 94 (38.7%) had diabetes mellitus, 49 (20.2%) had
chronic kidney disease with a creatinine >2 mg/dL, and 25
(10.3%) had chronic lung diseases. Concurrent comorbid-
ities were frequent, with 107 patients (44%) having 2
Figure 2. Patients with COVID-19 included in the study by country.
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increased with age being observed in 25.3%, 53.4%, and
64.2% in recipients aged <60 years, 60 to 70 years, or >70
years, respectively.
Immunosuppressive Drugs and Other Drugs
Tacrolimus (TAC) and cyclosporine A (CsA) were
considered as the main immunosuppressive drugs. Because
some of the patients were off a calcineurin inhibitor (CNI),
the proportion of patients receiving each immunosuppres-
sive drug or combination of drugs was also obtained. At the
time of analysis, 162 patients (66.7%) were on TAC, alone
or in combination, 29 (11.9%) were on CsA alone or in
combination, 119 (49.0%) were on mycophenolate mofetil
(MMF) alone or in combination, and 37 (15.2%) were on
mammalian target of rapamycin inhibitors alone or in
combination (Table 1).Clinical Presentation and Course of Liver
Transplant Recipients With COVID-19
At the time of diagnosis, the most commonly self-
reported symptoms included fever in 190 patients
(78.2%), cough in 143 (58.8%), dyspnea in 82 (33.7%),
muscle pain or asthenia in 90 (37.0%), anosmia or dys-
geusia in 21 (8.6%), and diarrhea in 55 (22.6%). Radiologic
findings on computed tomography scan or on chest radi-
ography showed typical ground-glass opacities in 145 pa-
tients (59.7%) (Table 2). Overall, 137 patients (56.4%)
required respiratory support during hospitalization, with 26
requiring noninvasive ventilation and 25 mechanical venti-
lation (Table 2). Specific anti–SARS-CoV-2 treatment was
administered to 149 patients: 116 (47.7%) were treated
with hydroxychloroquine alone or in combination, 41
(16.9%) with lopinavir-ritonavir, 34 (14.0%) with high
doses of corticosteroids, and 15 (6.2%) with tocilizumab.
Table 1.Baseline Characteristics of the Study Population
Variables
Place of management
Total (N ¼ 243) P valueHome (n ¼ 39) Ward (n ¼ 167) ICU (n ¼ 37)
Male sex 24 (61.54) 121 (72.46) 26 (70.27) 171 (70.37) .4051
Age at symptoms, ya,b 54 (37.0–61.0) 64 (57.0–72.0) 64 (58.0–68.0) 63 (55.0–69.0) <.0001
Age class at symptoms, ya,b <.0001
50 16 (41.03) 20 (11.98) 3 (8.11) 39 (16.05)
50–60 11 (28.21) 39 (23.35) 10 (27.03) 60 (24.69)
60–70 9 (23.08) 59 (35.33) 20 (54.05) 88 (36.21)
>70 1 (2.56) 48 (28.74) 4 (10.81) 53 (21.81)
Location of patient at occurrence of
symptomsb
.0119
Home 39 (100.00) 148 (88.62) 30 (81.08) 217 (89.30)
Hospital 0 (0.00) 19 (11.38) 7 (18.92) 26 (10.70)
Time between last LT and COVID-19
symptoms, y
6 (2.2–10.9) 9 (3.8–15.4) 5 (1.5–13.3) 8 (3.1–15.0) .0295
Time between last LT and COVID-19
symptoms
.1005
<1 year 5 (12.82) 19 (11.38) 7 (18.92) 31 (12.76)
1–5 years 12 (30.77) 32 (19.16) 11 (29.73) 55 (22.63)
5–10 years 9 (23.08) 34 (20.36) 7 (18.92) 50 (20.58)
10 years 10 (25.64) 81 (48.50) 10 (27.03) 101 (41.56)
Missing 3 (7.69) 1 (0.60) 2 (5.41) 6 (2.47)
Indication for LT
Decompensated cirrhosis 21 (53.85) 96 (57.49) 24 (64.86) 141 (58.02) .6034
Hepatocellular carcinoma 8 (20.51) 43 (25.75) 12 (32.43) 63 (25.93) .4933
Otherb 10 (25.64) 29 (17.37) 1 (2.70) 40 (16.46) .0226
Etiology
Alcohola 3 (7.69) 49 (29.34) 8 (21.62) 60 (24.69) .0149
After nonalcoholic steatohepatitis 2 (5.13) 10 (5.99) 6 (16.22) 18 (7.41) .1262
Hepatitis B virus 5 (12.82) 34 (20.36) 4 (10.81) 43 (17.70) .2492
Hepatitis C virus active or inactive 10 (25.64) 41 (24.55) 11 (29.73) 62 (25.51) .8282
Othera 20 (51.28) 49 (29.34) 10 (27.03) 79 (32.51) .0256
Missing 0 (0.00) 2 (1.20) 0 (0.00) 2 (0.82)
Body mass index, kg/m2 25.5 (22.0–28.9) 25.8 (23.4–29.4) 27.9 (24.5–29.9) 25.9 (23.4–29.4) .1701
Missing 3 (7.69) 18 (10.78) 1 (2.70) 22 (9.05)
Body mass index >30 kg/m2 7 (17.95) 30 (17.96) 9 (24.32) 46 (18.93) .7924
Comorbidities
Nonea,b 19 (48.72) 35 (20.96) 3 (8.11) 57 (23.46) <.0001
Diabetesb 8 (20.51) 67 (40.12) 19 (51.35) 94 (38.68) .0176
Hypertensionb,c 11 (28.21) 71 (42.51) 29 (78.38) 111 (45.68) <.0001
Chronic lung disease 3 (7.69) 20 (11.98) 2 (5.41) 25 (10.29) .5267
Chronic kidney diseased 4 (10.26) 37 (22.16) 8 (21.62) 49 (20.16) .2419
Coronary artery disease 3 (7.69) 9 (5.39) 5 (13.51) 17 (7.00) .2071
Other 4 (10.26) 34 (20.36) 5 (13.51) 43 (17.70) .2541
Number of comorbiditiesa,b .0002
0 19 (48.72) 35 (20.96) 3 (8.11) 57 (23.46)
1 11 (28.21) 57 (34.13) 11 (29.73) 79 (32.51)
2 9 (23.08) 75 (44.91) 23 (62.16) 107 (44.03)
Drugs
b-Blockers 6 (15.38) 34 (20.36) 10 (27.03) 50 (20.58) .4515
ACE inhibitors or angiotensin II receptor
antagonistsa,b
1 (2.56) 47 (28.14) 11 (29.73) 59 (24.28) .0025
Smoking .3508
Missing 0 (0.00) 1 (0.60) 1 (2.70) 2 (0.82)
No 35 (89.74) 151 (90.42) 30 (81.08) 216 (88.89)
Yes 4 (10.26) 15 (8.98) 6 (16.22) 25 (10.29)











Total (N ¼ 243) P valueHome (n ¼ 39) Ward (n ¼ 167) ICU (n ¼ 37)
Type of immunosuppressante
TAC 32 (82.05) 106 (63.47) 24 (64.86) 162 (66.67) .0831
MMF 15 (38.46) 80 (47.90) 24 (64.86) 119 (48.97) .0627
Steroids 7 (17.95) 35 (20.96) 14 (37.84) 56 (23.05) .0625
mTOR 5 (12.82) 27 (16.17) 5 (13.51) 37 (15.23) .8296
CsA 1 (2.56) 23 (13.77) 5 (13.51) 29 (11.93) .1188
Other 0 (0.00) 1 (0.60) 0 (0.00) 1 (0.41) >.9999
Combinations of immunosuppressant
CsA only 1 (2.56) 10 (5.99) 2 (5.41) 13 (5.35) .8264
CsA, MMF 0 (0.00) 7 (4.19) 2 (5.41) 9 (3.70) .3842
CsA, steroids 0 (0.00) 3 (1.80) 0 (0.00) 3 (1.23) .9999
CsA, MMF, steroids 0 (0.00) 3 (1.80) 1 (2.70) 4 (1.65) .5697
TAC only 12 (30.77) 36 (21.56) 6 (16.22) 54 (22.22) .2918
TAC, MMF 12 (30.77) 35 (20.96) 5 (13.51) 52 (21.40) .1806
TAC, mTOR 2 (5.13) 10 (5.99) 0 (0.00) 12 (4.94) .4209
TAC, steroids, or other 6 (15.38) 16 (9.58) 5 (13.51) 27 (11.11) .4473
TAC, MMF, mTOR 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
TAC, MMF, steroidsb 0 (0.00) 9 (5.39) 6 (16.22) 15 (6.17) .011
TAC, MMF, mTOR, steroids 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
MMF only 3 (7.69) 17 (10.18) 4 (10.81) 24 (9.88) .8966
MMF, mTOR 0 (0.00) 7 (4.19) 3 (8.11) 10 (4.12) .1712
MMF, steroids 0 (0.00) 2 (1.20) 1 (2.70) 3 (1.23) .4484
mTOR only 2 (5.13) 9 (5.39) 0 (0.00) 11 (4.53) .4577
mTOR, steroids 1 (2.56) 1 (0.60) 0 (0.00) 2 (0.82) .5286
Steroids only 0 (0.00) 2 (1.20) 0 (0.00) 2 (0.82) >.9999
Most recent values before symptoms
White blood cells, 109/L 5.1 (4.4–6.5) 5.2 (3.9–6.7) 6.0 (4.3–6.7) 5.2 (4.0–6.7) .9274
Bilirubin, mg/dL 0.8 (0.5–1.0) 0.6 (0.4–1.0) 0.6 (0.5–1.0) 0.7 (0.5–1.0) .7569
Creatinine, mg/dLa,b 1.0 (0.9–1.1) 1.1 (0.9–1.5) 1.2 (1.0–1.6) 1.1 (0.9–1.4) .019
ALT, U/L 23.0 (17.0–32.0) 20.0 (15.0–31.0) 23.0 (17.0–34.0) 20.0 (16.0–32.0) .3607
NOTE. Data are presented n (%) or median (1st–3rd quartile).
ACE, angiotensin converting enzyme; mTOR, mammalian target of rapamycin inhibitors.
aP value ward vs home .05.
bP value ICU vs home .05.
cP value ICU vs ward .05.
dPlasma creatinine >2 mg/dL.
ePatients can be treated with >1 therapy; therefore, percentages do not sum to 100.
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heparin, was started on COVID-19 diagnosis in 117 patients
(48.2%). Thrombotic events occurred in 7 of 204 (3.4%)
hospitalized patients, comprising 3 pulmonary embolisms, 2
deep vein thromboses, and 2 strokes.
An acute liver injury was observed in 56 patients with
previous persistently normal ALT levels, being in the flare
range in 10 patients. Acute rejection was reported in 3 pa-
tients. Notably, CNI had been withdrawn in 2 patients, and
the dose of mammalian target of rapamycin had been halved
in the third patient.
Forty-nine patients (20.2%) died after a median of 13.5
days (first–third quartile, 10–23 days) from the diagnosis of
COVID-19. Causes of death were respiratory failure in 39
patients (77.6%), end-stage liver disease with respiratory
failure in 2, end-stage liver disease without respiratory
failure in 1, hemorrhagic shock in 2, pulmonary embolism in1, metastatic cancer in 1 septic shock in 1, and septic
complication from tracheal fistula in 1. Overall Kaplan-Meier
survival from the date of COVID-19 symptoms is given in
Figure 3. Estimated a probability of survival was 88.2%
(95% confidence interval [CI], 82.5%–92.1%) at 30 days
and 84.4% (95% CI, 77.7%–89.2%) at 90 days.Clinical Features and Outcomes of Liver
Transplant Recipients With COVID-19 Treated at
Home, in General Wards, and in Intensive Care
Units
Baseline characteristics of patients with less severe
symptoms who could be treated at home and those with
more severe symptoms requiring hospitalization in general
wards and ICUs are reported in Table 2. Patients treated at
home were younger, had fewer comorbidities, and were
Table 2.Clinical Presentation and Course After COVID-19 Symptoms
Variable
Place of management
Total (N ¼ 243) P valueHome (n ¼ 39) Ward (n ¼ 167) ICU (n ¼ 37)
Symptoms: at clinical diagnosis
Fever >37.2Ca 25 (64.10) 137 (82.04) 28 (75.68) 190 (78.19) .0468
Cough 21 (53.85) 106 (63.47) 16 (43.24) 143 (58.85) .0609
Polypnea or dyspneaa,b,c 4 (10.26) 57 (34.13) 21 (56.76) 82 (33.74) .0001
Diarrheaa 3 (7.69) 46 (27.54) 6 (16.22) 55 (22.63) .0171
Anosmia and dysgeusiaa 9 (23.08) 10 (5.99) 2 (5.41) 21 (8.64) .0061
Muscle paina 13 (33.33) 24 (14.37) 4 (10.81) 41 (16.87) .0098
Confusion 0 (0.00) 4 (2.40) 3 (8.11) 7 (2.88) .0969
Thoracic pain 3 (7.69) 11 (6.59) 1 (2.70) 15 (6.17) .717
Asthenia 11 (28.21) 34 (20.36) 4 (10.81) 49 (20.16) .1669
Other 4 (10.26) 11 (6.59) 0 (0.00) 15 (6.17) .1591
Time between symptoms and positive
test, d b
9 (3–19) 5 (2–9) 3 (0–7) 4 (2–10) .0226
Chest x-ray or thorax CT scan
Noa,b 16 (41.03) 8 (4.79) 4 (10.81) 28 (11.52) <.0001
Yes, normalb,c 15 (38.46) 51 (30.54) 0 (0.00) 66 (27.16) .0002
Yes, ground-glass opacitiesa,b,c 7 (17.95) 106 (63.47) 32 (86.49) 145 (59.67) <.0001
Yes, lobar opacitiesc 1 (2.56) 6 (3.59) 7 (18.92) 14 (5.76) .0044
Ground-glass or lobar opacitiesa,b,c 8 (20.51) 108 (64.67) 33 (89.19) 149 (61.32) <.0001
Respiratory supportc <.0001
Oxygen support 1 (50.00) 78 (79.59) 7 (18.92) 86 (62.77)
Noninvasive ventilation 1 (50.00) 17 (17.35) 8 (21.62) 26 (18.98)
Mechanical ventilation 0 (0.00) 3 (3.06) 22 (59.46) 25 (18.25)
Added lung infection
Noneb,c 39 (100.00) 154 (92.22) 25 (67.57) 218 (89.71) <.0001
Bacterialb 0 (0.00) 11 (6.59) 7 (18.92) 18 (7.41) .0064
Fungalc 0 (0.00) 1 (0.60) 5 (13.51) 6 (2.47) .0011
Other 0 (0.00) 2 (1.20) 0 (0.00) 2 (0.82) >.9999
Renal replacement therapyb,c 0 (0.00) 10 (5.99) 11 (29.73) 21 (8.64) <.0001
Vasoactive drugs (NA)b,c 1 (2.56) 1 (0.60) 19 (51.35) 21 (8.64) <.0001
Myocarditis 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
Peak laboratory values
Bilirubin, mg/dLc 0.8 (0.5–1.1) 0.7 (0.4–1.0) 1.2 (0.8–2.7) 0.8 (0.5–1.2) .0034
International normalized ratiob,c 1.1 (1.0–1.2) 1.1 (1.1–1.3) 1.3 (1.1–1.7) 1.1 (1.1–1.3) .0039
Creatinine, mg/dLb,c 1.0 (0.9–1.6) 1.2 (0.9–1.8) 2.2 (1.2–4.0) 1.3 (0.9–2.0) .0009
ALT, U/Lb,c 28.0 (19.0–39.0) 32.0 (19.0–51.5) 59.5 (32.5–134.5) 34.0 (20.0–55.0) .0014
COVID-19 therapy
Nonea,b 33 (84.62) 46 (27.54) 15 (40.54) 94 (38.68) <.0001
Lopinavir/ritonavira,b 0 (0.00) 35 (20.96) 6 (16.22) 41 (16.87) .007
Hydroxychloroquinea,b,c 4 (10.26) 99 (59.28) 13 (35.14) 116 (47.74) <.0001
High-dose steroidsa,b 0 (0.00) 26 (15.57) 8 (21.62) 34 (13.99) .0144
Remdesevir 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
Tocilizumab 0 (0.00) 11 (6.59) 4 (10.81) 15 (6.17) .0962
Azythromicina 2 (5.13) 57 (34.13) 8 (21.62) 67 (27.57) .0009
Otherb 1 (2.56) 15 (8.98) 8 (21.62) 24 (9.88) .0215
Immunosuppression changes
Yesa,b 4 (10.26) 71 (42.51) 22 (59.46) 97 (39.92) <.0001
Stop CNI 0 (0.00) 11 (6.59) 5 (13.51) 16 (6.58) .0441
25%-50% reduction in CNI 2 (5.13) 28 (16.77) 8 (21.62) 38 (15.64) .1091
Stop antimetabolitesb 1 (2.56) 26 (15.57) 8 (21.62) 35 (14.40) .0455
Stop mTOR inhibitors 0 (0.00) 9 (5.39) 1 (2.70) 10 (4.12) .3305
Other 1 (2.56) 5 (2.99) 0 (0.00) 6 (2.47) .1479











Total (N ¼ 243) P valueHome (n ¼ 39) Ward (n ¼ 167) ICU (n ¼ 37)
Outcomea,b,c <.0001
Alive 39 (100.00) 138 (82.63) 17 (45.95) 194 (79.84)
Dead 0 (0.00) 29 (17.37) 20 (54.05) 49 (20.16)
Time between symptoms and last
follow-up, d b,c
70 (48–88) 66 (42–88) 29 (17–75) 65 (35–87) .007
Missing 3 (7.69) 1 (0.60) 2 (5.41) 6 (2.47)
Cause of death
Refractory pneumonia 23 (79.31) 15 (75.00) 38 (77.55) .7405
Liver-related death
Without lung failure 1 (3.45) 0 (0.00) 1 (2.04) >.9999
With lung failure 2 (6.90) 1 (5.00) 3 (6.12) >.9999
Other 3 (10.34) 4 (20.00) 7 (14.29) .4221
Heparina,b <.0001
Missing 13 (33.33) 20 (11.98) 6 (16.22) 39 (16.05)
No 24 (61.54) 53 (31.74) 10 (27.03) 87 (35.80)
Yes 2 (5.13) 94 (56.29) 21 (56.76) 117 (48.15)
Average CNI level pre–COVID-19 .0235
No CNI 4 (10.26) 5 (2.99) 1 (2.70) 10 (4.12)
CsA 50 ng/L 1 (2.56) 6 (3.59) 4 (10.81) 11 (4.53)
CsA 50–100 ng/L 1 (2.56) 2 (1.20) 0 (0.00) 3 (1.23)
CsA >100 ng/L 0 (0.00) 35 (20.96) 6 (16.22) 41 (16.87)
TAC 4 ng/mL 3 (7.69) 22 (13.17) 6 (16.22) 31 (12.76)
TAC 4–6 ng/mL 10 (25.64) 25 (14.97) 6 (16.22) 41 (16.87)
TAC >6 ng/mL 6 (15.38) 25 (14.97) 6 (16.22) 37 (15.23)
NOTE. Data are presented n (%) or median (1st–3rd quartile).
CT, computed tomography; mTOR, mammalian target of rapamycin; NA, noradrenaline.
aP value ward vs home .05
bP value ICU vs home .05
cP value ICU vs ward .05
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LIVERmore frequently receiving TAC as the primary immuno-
suppressant. Kaplan-Meier survival after stratification by
place of management, at home, general ward, or ICU is
provided in Figure 3. Patients managed at home survived,
whereas the probability of survival at 30 days was 93.1%
(95% CI, 86.7%–96.5%) and 57.0% (95% CI, 37.6%–
72.4%), respectively, for patients in ward and in ICUs, and
it declined to 89.8% (95% CI, 82.1%–94.3%) and 46.6%
(95% CI, 26.2%–64.6%) at 90 days. Notably, 12 patients
with advanced COVID-19 disease were not admitted to an
ICU, 8 because they were deemed too sick for the ICU due
to a combination of advanced age and severe comorbidities
and 4 because ICUs were overwhelmed.Factors Associated With Death
Factors by univariable analysis significantly associated
with death were increased age of the recipient, time from
LT, diabetes, chronic kidney disease, number of comorbid-
ities, and use of TAC (Table 3). After multivariable analysis,
advanced age (>70 vs <60 years) remained independently
associated with an increased mortality risk (hazard ratio,
4.16; 95% CI, 1.78–9.73), whereas use of TAC was
confirmed independently associated with a reducedmortality risk (hazard ratio, 0.55; 95% CI, 0.31–0.99). The
Kaplan-Meier survival curves stratified by age (>70 or <70)
and type of immunosuppressant (TAC vs non-TAC) may be
helpful for the clinician to better understand the individual
risk (Supplementary Figure 1).
Because the number of comorbidities increased with the
increasing age of the recipient, a second model excluding
age was constructed. This allowed diabetes and chronic
renal failure to emerge as predictors of mortality, their ef-
fect having been shadowed in the first model by the domi-
nant effect of age (Supplementary Table 1).
The interplay among age of the recipient, primary
immunosuppressant, and chronic renal failure is summa-
rized in Supplementary Table 2 and Supplementary
Figure 2, where the negative impact of chronic kidney dis-
ease is dramatically evident in recipients not maintained on
TAC. Finally, in Supplementary Table 3, patients receiving
TAC-based vs non–TAC-based regimens are compared with
respect to some relevant clinical variables such as age, time
from transplant, chronic renal failure, concurrent exposure
to angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker, and presence of hepatocellular carcinoma.
In fact, patients receiving TAC were younger and had fewer
comorbidities, these variables being potentially associated
Figure 3. Kaplan-Meier survival curve from the date of COVID-19 symptoms (A) overall and (B) stratified by place of
management.








with a better outcome. Conversely patients on TAC were
much less frequently treated with angiotensin-converting
enzyme or angiotensin receptor blocker inhibitors, this
therapy being associated with a better outcome. All these
variables were included in the multivariable analysis that
confirmed the independent protective role of TAC.Discussion
As more than 200 countries worldwide are still strug-
gling with the COVID-19 pandemic, all solid-organ trans-
plant recipients are at risk of infection and poor outcome
due to chronic immunosuppression, high rates of comor-
bidities, advanced age, and frequent hospitalization. We
have analyzed the characteristics, management, and
outcome of a large multinational European cohort of LT
recipients with symptomatic SARS-CoV-2 infection.
Rates of hospitalization and death in the current study
were 85% and 20.2%, confirming what we already showed
in our preliminary report on the first 103 patients,7 where
some patients were still experiencing their disease course.
These findings concur with the 23% mortality risk reported
by Webb et al,6 but compare unfavorably with the 12%
mortality risk observed by Becchetti et al,9 possibly due to
the lower percentage of patients requiring hospitalization in
this latter study. Our study confirmed that abdominal
symptoms and, more specifically, diarrhea are at least twice
more frequent than in the general population9 and are
possibly associated to MMF. This hypothesis is supported bythe fact that almost 50% of the 26 patients maintained on
MMF as the primary immunosuppressant had diarrhea as
presenting symptom. Clinicians should therefore be vigilant
and consider SARS-CoV-2 testing in transplant recipients
presenting with diarrhea, particularly if using MMF.
However, the main finding of the present study is the
significant variation in mortality risk with both age of the
recipients and use of TAC as immunosuppressant. The role
of advanced age confirms what has been extensively
observed in the general population, with patients older than
70 having an increased 4-fold mortality risk.11-14 The lower
risk of death for patients maintained on TAC was unex-
pected and to our knowledge has not been previously re-
ported. In particular Becchetti et al9 could not explore this
association in their prospective cohort of 57 LT recipients
with COVID-19 because the great majority of their patients
were receiving TAC. Notably, in our analysis, the beneficial
impact of TAC was robust and persisted after controlling for
various confounders. The biological explanation of the po-
tential favorable role of TAC is unknown but may be dual:
inhibition of viral replication and interaction with the im-
mune response. Some studies have shown that CoV repli-
cation, depends on active immunophilin pathways and that
TAC is capable of strongly inhibiting the growth of some
human CoV, notably SARS CoV-1, probably by binding the
immunophilin FK506-binding proteins, although not spe-
cifically SARS-CoV-2.10,15,16
Another potential driver of the TAC protective effect
could be related to the immunosuppressive property of this
Table 3.Results From Univariate and Multivariate Analysis of Predictors of Mortality, From Cox’s Proportional Hazard
Regression Models
Variable
Univariate models Multivariate models
HR (95% CI) P value HR (95% CI) P value
Age
Linear (1-year increase) 1.06 (1.03–1.10) <.0001
60–70 vs 60 years 2.58 (1.12–5.94) .0255 2.20 (0.94–5.13) .068
>70 vs 60 years 5.49 (2.42–12.48) <.0001 4.16 (1.78–9.73) .001
Sex (male vs female) 1.39 (0.71–2.73) .3438
Indication for LT
Decompensated cirrhosis 1.11 (0.61–2.00) .736
Hepatocellular carcinoma 1.25 (0.67–2.34) .4846
Other 0.63 (0.25–1.61) .3362
Time between LT and COVID-19 symptoms (1-year increase) 1.05 (1.01–1.09) .0054
Body mass index (1-unit increase) 1.00 (0.94–1.07) .9936
Comorbidities
Diabetes 1.98 (1.11–3.54) .0212
Hypertension 1.76 (0.98–3.17) .0584
Chronic lung disease 0.55 (0.17–1.76) .3126
Chronic kidney diseasea 2.20 (1.19–4.08) .0123 1.72 (0.92–3.22) .0912
Coronary artery disease 1.37 (0.49–3.81) .5518
Other 1.71 (0.89–3.31) .1095
Comorbidities, n
1 vs 0 3.54 (1.02–12.33) .0468
2 vs 0 5.63 (1.72–18.50) .0044
Smoking (yes vs no) 1.62 (0.72–3.63) .241
Type of immunosuppressant
CsA vs all other 2.29 (1.13–4.60) .0209
TAC vs all other 0.43 (0.24–0.77) .0042 0.55 (0.31–0.99) .0472
MMF vs all other 1.30 (0.73–2.33) .3704
mTOR inhibitors vs all other 1.37 (0.66–2.84) .3969
Treatment with ACE inhibitors or angiotensin II receptor
antagonists (yes vs no)
1.92 (1.06–3.49) .0328
Country
Spain vs Other 1.52 (0.67–3.48) .3178
Italy vs Other 1.34 (0.54–3.34) .5253
France vs Other 1.48 (0.55–3.94) .4355
Center recruiting more than 9 patients vs other centers 1.47 (0.82–2.65) .1993
NOTE. Bold values are statistically significant (P < .05).
ACE, angiotensin converting enzyme; CT, computed tomography; HR, hazard ratio; mTOR, mammalian target of rapamycin.
aPlasma creatinine >2 mg/dL.
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LIVERCNI.17 By inhibiting calcineurin and suppressing the early
phase of T-cell activation, TAC reduces the production of
many cytokines, notably proinflammatory cytokines, as
tumor necrosis factor-a and interferon-g, and possibly
mitigates the cytokine storm that characterizes stage III
COVID-19. Interestingly, this background recently prompted
a group of Spanish investigators to test the effect of TAC in
combination with steroids in the management of COVID-19
occurring in immunocompetent individuals (clinical-
trials.gov/ct2/show/NCT04341038). While waiting for
studies on larger cohorts of transplant recipients that wouldallow a more precise estimate of the protective effect of
TAC, reducing or withdrawing the doses of TAC during
COVID-19 should be discouraged, if not indicated for other
clinical reasons.
The role of comorbidities as relevant risk factors for
mortality has been clearly demonstrated in the general
population with COVID-19.18 Despite being highly preva-
lent among LT recipients,19 neither a specific comorbidity
nor a combination of comorbidities emerged as indepen-
dently associated with outcome. This is at least partly
explained by the dominant effect of age as comorbidities
Table 4.European Liver Transplantation Association/ European Liver Transplant Registry COVID-19 Registry for Liver
Transplant Candidates and Recipients: Collaborators With Affiliations
1. Division of Transplantation, Department of Surgery, Medical University of Vienna, Austria: Gabriela Berlakovich, Dagmar
Kollmann, Georg Györi
2. Universitair Ziekenhuis Antwerpen, Edegem, Belgium: Dirk Ysebaert, Patrick Hollants
3. Universitair Ziekenhuis Dienst voor Algemene en Hepatopancreaticobiliaire Heelkunde en Levertransplantatie, Ghent, Belgium:
Frederik Berrevoet, Aude Vanlander
4. Universitair Ziekenhuis, Dienst Voor Levertransplantatie En Digestieve Heelkunde, Ghent, Belgium: Frederck Berrevoet, Eric
Hoste, Christel Walraevens, Roberto Ivan Troisi
5. Liver Transplant Programme, University Leuven, Belgium: Jacques Pirenne, Frederick Nevens, Natalie Vandenende
6. CHU Liege,University of Liege, Belgium: Oliver Detry, Josee Monard, Nicolas Meurisse
7. Cliniques Universitaires Saint Luc, Catholic University of Louvain, Brussels, Belgium: Olga Ciccarelli
8. Hopital Erasme Universite Libre De Bruxelles, Department of Abdominal Surgery, Brussels, Belgium: Valerio Lucidi
9. Hopital Cantonal Universitaire De Geneve, Departement De Chirurgie, Geneva, Switzerland: Giulia Magini, Thierry Berney,
Anne-Catherine Saouli
10. University Hospital Copenhagen, Department for Surgery and Transplantation Rigshospitalet, Copenhagen, Denmark:
Allan Rasmussen
11. Hôpital De La Croix Rousse, Chirurgie Générale Et Digestive, Lyon, France: Sylvie Radenne, Mickael Lesurtel
12. Hôpital Henri Mondor, Service d’Hepatologie, Créteil, France: Christophe Duvoux, Norbert Ngongang
13. Hôpital Paul Brousse, Centre Hépato Biliaire, Villejuif, France: Audrey Coilly
14. C.H.R.U. De Strasbourg, Hôpital Hautepierre, Strasbourg, France: Francoise Faitot
15. Hepatogastroenterology Unit, Hopital Trousseau, C.H.R.U. de Tours, Tours, France: Laure Elkrief
16. Hôpital Bicêtre, Hépatologie et Transplantation Hépatique Pédiatriques, AP-HP Université Paris-Saclay, Le Kremlin-Bicêtre,
France: Emmanuel Gonzales
17. The Queen Elizabeth Hospital, Queen Elisabeth Medical Center, Birmingham, United Kingdom: Darius Mirza, Thamara Perera,
Hann Angus
18. University of Edinburgh Royal Infirmary, Liver Transplantation Unit, Edinburgh, United Kingdom: Gabriel Oniscu, Chris Johnston
19. Papa Giovanni XXIII Hospital, Chirurgia E Centro Trapianti Di Fegato, Bergamo, Italy: Luisa Pasulo, Michela Guizzetti,
Marco Zambelli
20. Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy: Cristina Morelli, Giovanni Vitale
21. Istituto Nazionale Tumori Milano, Department of Hepatology, Hepato-pancreatic-biliary Surgery and Liver Transplantation,
Istituto Nazionale Tumori, Milan, Italy: Sherrie Bhoori, Vincenzo Mazzaferro, Roberta Elisa Rossi
22. Ospedale Maggiore Di Milano, U.O. Chirurgia Generale E Dei Trapianti, Milano, Italy: Federica Invernizzi, Francesca Donato,
Giorgio Rossi
23. Ospedale Niguarda Ca Granda, Hepatology and Gastroenterology Unit and Transplant Surgery Unit, Milano, Italy: Luca S Belli, Giovann
Perricone, Raffaella Viganò, Chiara Mazzarelli, Luciano De Carlis
24. University of Modena E Reggio Emilia, Policlinico Di Modena, Modena, Italy: Fabrizio Di Benedetto, Paolo Magistri,
Antonia Zuliani
25. Ospedale Cisanello, U.O. Trapiantologia Epatica Universitaria Azienda Ospedaliera, Pisa, Italy: Paolo De Simone, Paola Carrai,
Stefania Petruccelli
26. Liver Transplant Unit, AOU Città della Salute e della Scienza di Torino, Torino, Italy: Damiano Patrono, Silvia Martini,
Renato Romagnoli
27. University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands:
Aad Van Der Berg, Frank Cuperus
28. Erasmus MC, Transplant Insitute, University Medical Center Rotterdam, Department of Surgery, Divion of Hepatobiliry Surgery and Live
Transplantation, Rotterdam, The Netherlands: Wojciech Polak, Herold Metselaar
29. Hospital Gal De Santo Antonio, Department of Surgery and Organ Transplantation, Porto, Portugal: Jorge Daniel
30. Hospital General Universitario De Alicante, Unidad Transplantes Hepatico, Alicante, Spain: Gonzalo Rodriguez, Sonia Pascual











31. Hospital Clinic I Provincial De Barcelona, Gastrointestinal Surgery Department, Barcelona, Spain: Costantino Fondevila,
Jorde Colmenero
32. Hospital Universitari De Bellvitge, Unidad De Trasplante Hepatico Unidad De Trasplante Hepatico, Barcelona, Spain:
Laura LLado, Carme Baliellas
33. Hospital Universitari Vall D Hebron; Barcelona, Spain: Lluis Castells, Isabel Campos-Varela, Liver Unit; Ernest Hidalgo,
Liver Transplant Unit
34. Hospital Universitario 12 de Octubre, HBP And Transplant Unit, General Surgery, Madrid, Spain: Carmelo Loinaz Segurola,
Alberto Marcacuzco, Felix Cambra
35. Hospital Gregorio Maranon, Liver Transplant Unit, Madrid, Spain: Magdalena Salcedo Plaza, Fernando Diaz-Fontenla
36. Hospital Universitario Puerta de Hierro, Unidad de Trasplante Hepatico, Madrid, Spain: Valentin Cuervas-Mons,
Ana Arias Milla, Alejandro Muñoz
37. Liver Transplant Unit, Hospital Virgen del Rocio, Seville, Spain: Jose Maria Alamo
38. Cirurgia HPB y Transplante Hepatico, Hospital Universitario de Badajoz, Spain: Gerardo Blanco
39. Hospital Universitario, Virgen De La Arrixaca, El Palmar (Murcia), Spain: Victor Lopez Lopez.
40. Clinica Universitaria, Universidad De Navarra, Facultad De Medicina, Pamplona, Spain: Pablo Marti-Cruchaga
41. Hospital Universitario Marques De Valdecilla, Unidad De Traspante Hepatico, Santander, Spain: Rodriguez San Juan
42. Hospital Universitario Virgen De La Nieves, Servicio De Cirugia General, Granada, Spain: Esther Brea Gomes
43. Huddinge Hospital, Department of Transplantation Surgery, Huddinge, Sweden: Bo Goran Ericzon, Carl Jorns
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LIVERincreased with the increasing age of the recipients.
Nevertheless, in our exploratory analysis, chronic renal
failure, defined by a serum creatinine >2 mg/dL, main-
tained a trend of significance (P < .1) even if shadowed by
the dominant effect of increasing age. Notably, the negative
impact of renal failure on survival was particularly rele-
vant in patients who were not receiving TAC, once again
pointing to its possible protective role against COVID-19, at
least in LT recipients.
Finally, therapy for COVID-19 differed across centers
and countries and varied over time with the increasing
knowledge in treating this new disease. Because large pro-
spective randomized trials have recently demonstrated that
corticosteroids and remdesivir are effective in severe cases,
whereas hydroxychloroquine and lopinavir-ritonavir are
not, new patients should be treated accordingly.20,21
This study has some strengths. It is, at the time of
writing, the largest cohort of consecutive transplant re-
cipients affected by COVID-19 with a relatively long median
follow-up of approximately 2 months. It focuses only on
symptomatic patients and analyzes the role of clinical fea-
tures at admission and diagnosis on mortality risk. The
quality of the data was guaranteed by maintaining constant
communications with the contributing centers. Finally, the
international multicentered pattern of the study copes with
any individual center effect.
Some limitations are also to be acknowledged. Firstly,
although we attempted to collect data on major covariables,
there remains the possibility of missing confounders. Sec-
ondly, we focused on symptomatic patients with confirmed
positive SARS-CoV-2 RT-PCR test despite test sensitivity
<80%. Thus, some patients were excluded.Conclusion
This study, including more than 240 LT recipients,
confirmed that 25% of patients requiring hospitalization for
COVID-19 died, the mortality risk being greater in patients
aged older than 70 and with medical comorbidities such as
impaired renal function and diabetes. Conversely, the use of
TAC was associated with an increased survival probability.
Although the biological explanation of this latter finding is
currently unknown, our preliminary evidence should
encourage clinicians to keep TAC at the usual dose because
it may be beneficial when treating COVID-19. A more precise
estimate of the protective effect of TAC requires studies on
larger cohorts of transplant recipients.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2020.11.045.References
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Supplementary Figure 1. Kaplan-Meier curves for survival from the date of COVID-19 diagnosis, stratified by age (2 cate-
gories) and main immunosuppressant. Cya, cyclosporin A; FK, tacrolimus; mTOR, mammalian target of rapamycin.
Supplementary Figure 2. Kaplan-Meyer curves for survival from the date of COVID-19 diagnosis show the interplay between
age of the recipient, primary immunosuppressant, and chronic renal failure (CRF). mTOR, mammalian target of rapamycin.
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Supplementary Table 1.Results From Multivariate Analysis
of Predictors of Mortality, From
Cox’s Proportional Hazard
Regression Models, Excluding Age
From the Predictors
Variable HR (95% CI) P value
Comorbidities
Diabetes 1.95 (1.06–3.58) .0313
Chronic kidney diseasea 1.97 (1.05–3.67) .0336




NOTE. Predictors with a P value .1 were retained in the
model. Bold values are statistically significant (P < .05).
HR, hazard ratio; mTOR, mammalian target of rapamycin
inhibitor.
aPlasma creatinine >2 mg/dL.
Supplementary Table 2.Estimated Probability of Survival 50 Days After the Symptoms, Stratified by Age (2 Categories), Main







at 50 days (95% CI)
 70 y TAC No 113 0.89 (0.82–0.94)
Yes 16 0.86 (0.55–0.96)
CsA/mTOR/MMF/other No 39 0.90 (0.75–0.96)
Yes 13 0.54 (0.25–0.76)
>70 y TAC No 16 0.75 (0.46–0.90)
Yes 10 0.77 (0.34–0.94)
CsA/mTOR/MMF/other No 20 0.50 (0.27–0.69)
Yes 7 0.29 (0.01–0.69)
NOTE. Estimates are based on Kaplan-Meier curves.
mTOR, mammalian target of rapamycin inhibitor
aPlasma creatinine >2 mg/dL.
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Supplementary Table 3.Baseline Characteristics of the Study Population, Stratified by Type of Calcineurin Inhibitor
Variables
Immunosuppressant
Total (N ¼ 243) P valueCsA/other (n ¼ 81) TAC (n ¼ 162)
Male sex 66 (81.48) 105 (64.81) 171 (70.37) .0073
Age at symptoms, y 68 (60.5–73.5) 61 (53.0–68.0) 63 (55.0–69.0)
Location of patient at occurrence of symptoms .4631
Home 74 (91.36) 143 (88.27) 217 (89.30)
Hospital 7 (8.64) 19 (11.73) 26 (10.70)
Place of management .0831
Home 7 (8.64) 32 (19.75) 39 (16.05)
Ward 61 (75.31) 106 (65.43) 167 (68.72)
ICU 13 (16.05) 24 (14.81) 37 (15.23)
Time between last LT and COVID-19 symptoms, y 12 (6.2–18.9) 7 (2.0–13.3) 8 (3.1–15.0)
Missing 1 (1.23) 5 (3.09) 6 (2.47)
Indication for LT
Decompensated cirrhosis 51 (62.96) 90 (55.56) 141 (58.02) .27
Hepatocellular carcinoma 21 (25.93) 42 (25.93) 63 (25.93) >.9999
Other 9 (11.11) 31 (19.14) 40 (16.46) .1118
Body mass index, kg/m2 26.3 (23.5–29.7) 25.7 (23.4–29.4) 25.9 (23.4–29.4) .6612
Chronic kidney diseasea 22 (27.16) 27 (16.67) 49 (20.16) .0546
Coronary artery disease 3 (3.70) 14 (8.64) 17 (7.00) .1548
Comorbidities, n .0003
0 11 (13.58) 46 (28.40) 57 (23.46)
1 20 (24.69) 59 (36.42) 79 (32.51)
2 50 (61.73) 57 (35.19) 107 (44.03)
Drugs
b-Blockers 20 (24.69) 30 (18.52) 50 (20.58) .2618
ACE inhibitors or angiotensin II receptor antagonists 33 (40.74) 26 (16.05) 59 (24.28) <.0001
Type of immunosuppressant
CsA 29 (35.80) 0 (0.00) 29 (11.93) <.0001
TAC 0 (0.00) 162 (100.00) 162 (66.67) <.0001
MMF 50 (61.73) 69 (42.59) 119 (48.97) .0049
mTOR inhibitor 23 (28.40) 14 (8.64) 37 (15.23) <.0001
Steroids 14 (17.28) 42 (25.93) 56 (23.05) .1316
Other 0 (0.00) 1 (0.62) 1 (0.41) >.9999
Outcome .0033
Alive 56 (69.14) 138 (85.19) 194 (79.84)
Dead 25 (30.86) 24 (14.81) 49 (20.16)
Time between symptoms and last follow-up, d 60 (23–83) 66 (39–87) 65 (35–87) .127
Missing 1 (1.23) 5 (3.09) 6 (2.47)
Cause of death
Refractory pneumonia 21 (84.00) 17 (70.83) 38 (77.55) .2695
Liver-related death
Without lung failure 0 (0.00) 1 (4.17) 1 (2.04) .4898
With lung failure 2 (8.00) 1 (4.17) 3 (6.12) >.9999
Other 2 (8.00) 5 (20.83) 7 (14.29) .2467
NOTE. Data are presented n (%) or median (1st–3rd quartile).
mTOR, mammalian target of rapamycin.
aPlasma creatinine >2 mg/dL.
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